Aldeyra announced completion of enrollment in the Phase 3 INVIGORATE-2 clinical trial of topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of allergic conjunctivitis.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALDX:
